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renin-angiotensin system (RAS) is subject to sex-specific modulation
by hormones and gene products. However, sex differences in the
balance between the vasoconstrictor/proliferative ACE/ANG II/AT1
axis, and the vasodilator/antiproliferative ACE2/ANG-(1–7)/MAS
axis are poorly known. Data in the rat have suggested the male-
specific Y-chromosome gene Sry to contribute to balance between
these two axes, but why the testis-determining gene has these func-
tions remains unknown. A combination of in silico genetic/protein
comparisons, functional luciferase assays for promoters of the human
RAS, and RNA-Seq profiling in rat were used to address if regulation
of Sry on the RAS is conserved in the homologous X-chromosome
gene, Sox3. Both SRY and SOX3 upregulated the promoter of Ang-
iotensinogen (AGT) and downregulated the promoters of ACE2, AT2,
and MAS, likely through overlapping mechanisms. The regulation by
both SRY and SOX3 on the MAS promoter indicates a cis regulation
through multiple SOX binding sites. The Renin (REN) promoter is
upregulated by SRY and downregulated by SOX3, likely through
trans and cis mechanisms, respectively. Sry transcripts are found in all
analyzed male rat tissues including the kidney, while Sox3 transcripts
are found only in the brain and testis, suggesting that the primary
tissue for renin production (kidney) can only be regulated by SRY and
not SOX3. These results suggest that SRY regulation of the RAS is
partially shared with its X-chromosome homolog SOX3, but SRY
gained a sex-specific control in the kidney for the rate-limiting step of
the RAS, potentially resulting in male-specific blood pressure regu-
lation.
renin angiotensin system; hypertension; Sox3; Sry; sex differences
THE RENIN-ANGIOTENSIN SYSTEM (RAS) is one of the most studied
hormonal systems in the physiological regulation of blood
pressure through renal and nonrenal mechanisms (16). Dys-
regulation of the RAS is considered a major factor in the
development of cardiovascular pathologies. It is generally
subdivided into two major axes that act to maintain homeosta-
sis, with each tissue/system having a unique combination of
proteins and peptides (9). These axes are: 1) the vasoconstric-
tor/proliferative axis of the RAS consisting of the carboxypep-
tidase angiotensin-I-converting enzyme (ACE), angiotensin II
(ANG II), the type 1 angiotensin II receptor (AT1) and 2) the
vasodilator/antiproliferative axis consisting of angiotensin I-
converting enzyme 2 (ACE2), angiotensin (1–7) [ANG-(1–7)],
the MAS receptor. It is now generally accepted that both axes
participate in the regulation of blood pressure and metabolism,
and, even more importantly, in the pathogenesis of cardiovas-
cular, renal, and metabolic diseases (58). Several reports have
shown differences between components such as plasma renin
activity and levels of angiotensinogen in human, mouse, and
rat models between males and females as previously reviewed
in the literature (55). However, few studies have observed and
analyzed the effects of sex differences in regulation and bal-
ance of the two axes of the RAS (26).
Studies of Y-chromosome consomic rats first suggested a
contribution of the male-specific chromosome to elevate blood
pressure (21), with characteristics in crosses of the consomic
rats to the testicular feminized rats suggesting an interplay
between genes on the Y chromosome and androgen signaling
(20). Dissection of the Y chromosome elucidated the Sry gene
as a candidate to elevate blood pressure in the rat (22, 65). Part
of the blood pressure elevation in the rat was due to changes in
the RAS (19, 40), a regulation that is seen by human SRY on
human RAS promoters (52, 53). Electroporation of Sry into the
kidney of normotensive rats elevates plasma renin (REN)
activity (19), an activity that is known to be elevated in human
males relative to females (28). Evidence points to a combina-
tion of sex hormones and SRY regulating promoter activity of
RAS genes, suggesting an elevation of the ACE/ANG II/AT1
axis and a depression of the ACE2/ANG-(1–7)/MAS axis (19,
23, 38, 40, 52, 53). As SRY is primarily known for its role in
testis determination (4), the regulation of the RAS and blood
pressure was not initially expected.
SRY is a member of the SOX transcription factor family that
plays important roles in regulating cell specialization and
differentiation (29). The SOX family is composed of 20 human
transcription factors, all sharing a homologous high-mobility
group (HMG) box domain first discovered in the SRY protein
(6). The HMG box of SOX transcription factors binds to DNA
with sequence specificity, resulting in both conserved tran-
scription factor recruitment (50) and architectural modification
by inducing a bend to DNA (49). Sry evolved from the Sox3
gene (12, 59), which in human is found on the X chromosome.
Thus Sry could have either maintained the regulation of the
RAS genes from Sox3 or gained this function de novo. With
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recent elucidation of critical genes maintained on the Y chro-
mosome (3), understanding the impact these genes have on
various disease phenotypes is of critical importance, especially
with a focus on similarities and differences between the Y-
chromosome genes and their homologous counterpart on the X
chromosome. We hypothesize that there is preserved promoter
regulation between SRY and SOX3 on the RAS genes, with
some possibility of sex differences in the regulation of RAS
components and ultimately blood pressure regulation. There-
fore, the aim of this study was to further evaluate mechanisms
of action, especially in the promoter regions of the RAS genes
that were previously shown to be modulated by SRY.
MATERIALS AND METHODS
Sry and Sox3 in silico comparisons. Nucleotide sequences for Sry
(321 total mammalian sequences) and Sox3 (34 total vertebrate
sequences from human to zebrafish) were aligned with ClustalW
codon in MEGA5 (62). Phylogenetic analysis was performed with all
Sry and Sox3 sequences to confirm none of the Sry sequences
clustered within the SOX3 sequences. The test statistic dN-dS was
used for detecting codons that have undergone selection, where dS is
the rate of synonymous substitutions and dN is the rate of nonsyn-
onymous substitutions. A positive value for the test statistic indicates
an overabundance of nonsynonymous substitutions. The normalized
dN-dS values were calculated for each codon, using the joint maxi-
mum likelihood reconstructions of ancestral states under a Muse-Gaut
model (45) of codon substitution and Tamura-Nei model (61) of
nucleotide substitution. Based on sequence alignments, those amino
acids conserved in all SRY and SOX3 sequences were colored red,
and those conserved in only SOX3 but not SRY in cyan onto the
structure of SRY-DNA (pdb 1j46). Amino acids were swapped in the
HMG box of SRY (using pdb 1j46) for those of SOX3. Models for
both SRY and SOX3 interaction with DNA were then energy mini-
mized with the AMBER03 force field (15) with a pKa of 7.4, water
density of 0.997 g/ml, and 0.9% NaCl mass fraction in YASARA
(32). Molecular dynamic simulations were performed for 3.25 nano-
seconds.
Promoter, evolutionary conserved region, and transcription factor
binding site analysis. SOX binding sites in each promoter were
detected using Genomatix MatInspector (8). All promoters cloned
except the ACE promoter contain predicted SOX binding sites.
Evolutionary conserved region (ECR) analysis was performed in
the ECR browser (48) using the parameters listed in the figure
legends for each analysis. Conserved regions were then analyzed
for conserved transcription factor binding sites between human and
rat using RVISTA (37) for all vertebrate transcription factor
binding sites.
Cloning. The pEF1 SOX effector plasmids cloning strategy was
previously published (52). Details for the various human pGL3
luciferase reporter constructs were also previously published (53).
Starting with the human REN(1444/8) pGL3 reporter construct,
we sequentially removed the three SOX binding sites, resulting in the
REN(1444/8) SOX mut reporter vector; i.e., the first site was
removed followed by sequence confirmation, then the second site, and
finally the third site. This was performed with phosphorylated primers
flanking each SOX binding site (Table 1), followed by PCR with
Phusion Hot Start II polymerase (Fermentas) and vector recircularized
with T4 ligase. We used the following two strategies to assess SOX
binding sites in the MAS promoter: 1) varying the size of the promoter
insert or 2) mutating a specific SOX binding site. Both were per-
formed using primer-directed mutagenesis (Table 1). All constructs
were sequence confirmed using BigDye Sanger sequencing on an ABI
3130xl genetic analyzer (Applied Biosystems). The SRY-MAS elec-
trophoresis mobility shift assay was performed as previously pub-
lished (52).
Cotransfection and luciferase assays in Chinese hamster ovary
cells. Twenty-four hours prior to transfection of Chinese hamster
ovary (CHO) cells, 5  104 cell/well were seeded on 24-well plates
and incubated overnight in Ham’s F12K medium (Sigma) supple-
mented with 10 mM HEPES and 10% fetal bovine serum (Atlanta
Biologicals) in a humidified atmosphere at 37°C and 5% CO2. We
selected CHO cells for the analysis for previously suggested
reasons (53). Each well was transiently cotransfected with 50 ng
effector plasmid (pEF1 vector), 500 ng firefly luciferase reporter
construct (pGL3 vector), and 500 pg of control Renilla vector.
Transfections with both SRY and SOX3 together were performed
by using 50 ng effector plasmid total: for example, 25 ng of SRY
with 25 ng of SOX3 for SRYSOX or 25 ng of SRY with 25 ng of
empty pEF1 vector for SRY alone. Luciferase assays were per-
formed using the Stop & Glo luciferase kit (Promega) according to
the manufacturer. Statistical analysis was performed on the SE of
Table 1. Primers used for mutagenesis of luciferase promoters
Construct Name Primer Name Primer Sequence
Renin SOXdel1 R1-RenSoxdel 5=-CAT CAG GTT TGA CTT ACA GG-3=
L1-RenSoxdel 5=-CTT GAA TGT AAT CAG ACA CAG-3=
Renin SOXdel2 R2-RenSoxdel 5=-TGT TAA AGA TGT ATA GGA AC-3=
L2-RenSoxdel 5=-TGT CTG TAT ATT TCC TTA TC-3=
Renin SOXdel3 R3-RenSoxdel 5=-TGA AAC CCC ATC TCC ACT AA-3=
L3-RenSoxdel 5=-AGG CTG GTC TGG AAC T-3=
MAS(1123/4) R-MAScleavage 5=-GGC TAG CAC GCG TAA GAG CTC G-3=
L3-MAScleavage 5=-GGA GTT CAA GAC CAG CCT CAC CAA CA-3=
MAS(377/4) R-MAScleavage 5=-GGC TAG CAC GCG TAA GAG CTC G-3=
L1-MAScleavage 5=-AGA ACT GGA AAT GGG TCC CGC ACA-3=
MutSOX-1855 R-MASSoxdel1 5=-CAA CGG CCC TCA AAC TGA TGT CAG TGC GTG AA-3=
L-MASSoxdel1 5=-CTG TTG CCG CAT TTT GCT TGA CTG CCT CCC TAC-3=
MutSOX-86 R-MASSoxdel7 5=-AAA GGG AGA AAT TCA GCT ATA AAT CAT AAT CTT CAT G-3=
L-MASSoxdel7 5=-TAT TCC AAT TCG GCG ATT TTC ATG GCT TTT TGT GTT TGT T-3=
RecSOX-86 R-MASSoxdel7W 5=-AAA GGG AGA AAT TCA GCT ATA AAT CAT AAT CTT CAT G-3=
L-MASSoxdel7W 5=-TAT TCC AAT TCA ACA ATT TTC ATG GCT TTT TGT GTT TGT T-3=
Mut2SOX-86 R-MASSoxdel8 5=-AAA GGG AGA AAT TCA GCT ATA AAT CAT AAT CTT CAT G-3=
L-MASSoxdel8 5=-TAT TCC AAT TCA ACT TGT TTC ATG GCT TTT TGT GTT TG-3=
To make each of the mutated promoter constructs the primers in this table were used. The 1st column shows the construct name as used in the study, the 2nd
column the individual primer names, and the 3rd column the primer sequences. For mutations, the SOX binding site is underlined and bolded with the DNA bases
to be mutated shown in italics.
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three or four independent experiments followed by Student’s t-test
to determine significant differences (P  0.05) relative to the
experimental control.
Sry and Sox3 expression in the rat. Initial work in the Fisher 344
Rat BodyMap project (71) did not annotate either Sry or Sox3
transcripts. Therefore, we used the Sry (EU984075.1) and Sox3
(XM_006227591.2) sequences from the rat to BLAST reads from the
various Sequence Read Archive (SRA) datasets of the Rat BodyMap
project (35). BLAST (2) was performed only on reads that were 98%
homologous with an E-value better than 1e-20. The number of
positive reads was converted into the RPKM, reads per kilobase per
million [(# of mapped reads)/(length of transcript in kilobases)/
(million mapped reads)]. For the global expression profile, all SRA
files for an individual tissue were pooled together for BLAST analysis
(16 total), only separated by the sex of the animal (male vs. female).
Three tissues were picked (testis, brain, and kidney) for profiling the
error between animals (n  4) and at each of four ages. The error was
calculated using the SE. Primate SRY (NM_003140.2, KP141769.1,
NM_001032836.1, DQ977342.1, EU294189.1) and SOX3 (NM_
005634.2, XM_004065361.1, NM_001193752.1, XM_001143467.3, XM_
005227560.1) sequences were analyzed for SRA datasets of the kidney
(SRX081994, SRX081951, SRX081930, SRX081966, SRX196347) and
testis (SRX081999, SRX081954, SRX081933, SRX081969, SRX358238)
for RPKM.
RESULTS
SRY has rapidly evolved from SOX3, resulting in differ-
ences in all domains outside of the DNA binding HMG box.
Among 34 species sequences for the SOX3 HMG box (repre-
senting a wide range of vertebrates) only one of the 76 amino
acids was not conserved (Fig. 1A). However, in the 321
sequences of SRY (found only in mammals) 26 amino acids
are not conserved. The larger number of SRY sequences,
compared with SOX3, represents the previous resources in-
vested in Sanger sequencing Sry throughout mammals primar-
ily for Y-chromosome phylogenetic work, while the few Sox3
sequences are mostly from whole genomes sequences of spe-
cies. To address whether SRY and SOX3 DNA binding sites
remain similar, codons of Sox3 that are under selective pres-
sure (more negative dN-dS, Fig. 1B) were identified. Amino
Fig. 1. Functional conservation in SRY and SOX3. A: sequence alignment of the high-mobility group (HMG) box of human SOX3 and SRY with conservation
shown below each in multiple species. Those sites marked with an asterisk (*) are 100% conserved in all species and those with a colon (:) are functionally
conserved. Amino acids in red are conserved in all SRY and SOX3, while those in cyan are conserved in SOX3 only. Amino acids highlighted in yellow are
those in which mutations in SRY are associated with sex reversal (50). B: normalized values for each amino acid’s (x-axis) nonsynonymous rate (dN) minus the
synonymous rate (dS) for the 34 sequences of Sox3. Values more negative suggest codon selection. C: known structure of SRY bound to DNA (pdb file 1j46)
with the amino acids conserved among all SRY and SOX3 sequences shown in red and those conserved in SOX3 but not SRY shown in cyan. DNA is shown
in gray. D: root-mean squared fluctuation (RMSF) for each amino acid over a 3.25 nanosecond molecular dynamic simulation for the known structure of SRY
(red) or the modeled SOX3 (cyan) indicate similarities of the 2 proteins. E: the pEF1 expression vectors for either human SRY (light gray) or SOX3 (darker gray)
were transfected into CHO cells along with a pGL3 vector containing the human promoter (shown on the bottom) of various RAS genes driving the production
of luciferase. Each sample was normalized to an empty vector control of pEF1 (black). Error bars are shown as the SE. Each sample is compared with the control
for each promoter. *Significant differences (P  0.05).
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acids 11, 30, 45, 60, and 66 have dN-dS 10 and are
conserved in all or most of the SRY sequences. When conser-
vation of amino acids for SRY and SOX3 sequences are
mapped onto the protein structure, a highly conserved DNA
contact is revealed (Fig. 1C), suggesting both proteins bind to
DNA with similar sequence specificity. Modeling the SOX3
protein reveals similar molecular dynamics for all amino acids
between SRY and SOX3 (Fig. 1D).
Utilizing the previously designed luciferase vectors con-
trolled by the various RAS promoters, we tested SRY and
SOX3 for promoter regulations (Fig. 1E). The promoter of
AGT was upregulated by both SRY and SOX3, while the
promoters of ACE2, AT2, and MAS were downregulated by
both SRY and SOX3. The only promoter that was differentially
regulated was that of the gene REN, which was upregulated by
SRY and downregulated by SOX3.
The MAS promoter was previously shown to be regulated by
multiple SOX subfamily members and shown to be directly
bound by SRY (52); therefore, we elected to characterize the
shared binding sites between SRY and SOX3 on this promoter.
Fig. 2. Functional SOX binding sites in the MAS promoter. A: evolutionary conserved region (ECR) browser analysis of the MAS pGL3 promoter construct for
the rat (rn4), mouse (mm10), dog (canFam2), and monkey (rh2Mac2). Regions in red and green share conservation with human based on 20 bp stretches sharing
50% homology. Below the ECR is the location of various landmarks of the promoter vector such as sites used to create cleavage series (2222, 1123, and
377), predicted SOX binding sites (blue), in vitro confirmed SOX binding site (red), the location of the TATA box (290), proposed transcriptional start site
(TSS, 266), translational start site (ATG, 1), and ENCODE transcription factor binding with relative score and cell line of observation. B: the human MAS
promoter treated with various SOX A/B proteins, all of which significantly repress the promoter. C: luciferase production of 4 MAS promoter constructs with
differing lengths, all made relative to the full-length MAS (2222/4) construct regulation level. D: promoter analysis of 4 MAS promoter constructs transfected
with control (black), SRY (light gray) or SOX3 (dark gray) vectors. Total number of SOX binding sites in each construct is shown below the graph. E: mutations
to the MAS(2222/4) promoter construct at 2 of the 10 SOX binding sites (1855 or 86) result in elevation of promoter activity. Data are shown as the raw
luciferase-Renilla ratio. F: as the MAS(2222/4)MutSOX-86 showed a trend in altering regulation and was previously shown to be an in vitro binding site
for SRY, the site was investigated with the smaller MAS minimal promoter, MAS(377/4). The SOX binding site was mutated to 2 separate sequences,
MAS(377/4)MutSOX-86 and MAS(377/4)Mut2SOX-86, resulting in elevation of promoter activity. One of the mutations was repaired to recover the
SOX binding site, MAS(377/4)RecSOX-86, confirming only this site was altered in the promoter mutagenesis. G: the sequence for the SOX binding site at
86 was synthesized with a biotin tag and EMSA performed using both His- and GST-tagged Sry proteins, confirming that SOX proteins can bind to this element.
Error bars for all graphs are shown as the SE. Each sample is compared with the control for each promoter. *Significant differences (P  0.05) relative to the
control.
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The MAS promoter contains no ECRs, with sequence diver-
gence in all species for the promoter and the 5=-untranslated
region (UTR) (Fig. 2A), reducing our ability to use evolution-
ary genomics to decipher the molecular binding sites. There-
fore, the binding sites for SOX were tested using two different
approaches: 1) a cleavage series to generate MAS promoters of
various sizes and 2) point mutations within two of the SOX
binding sites. The full MAS promoter used [MAS(2222/4)]
contains 10 predicted SOX binding sites. This full-length
construct is regulated by all of the SOX A/B protein family
members (Fig. 2B). Cleaving part of the MAS promoter such
that there are seven possible SOX binding sites [MAS(1123/
4)] or one possible binding site [MAS(377/4)] had little
effect on relative luciferase production (Fig. 2C), with the
exception being the five possible binding site MAS(847/4)
constructs that had significant upregulation of the promoter.
The addition of SRY or SOX3 to the cells treated with the
various sized promoter constructs showed a complete loss of
SRY/SOX3 repression only on the shortest of the constructs
[MAS (377/4), Fig. 2D], suggesting that the cluster of
SOX binding sites between 847 and 377 are important for
promoter regulation.
To assess if the SOX binding sites outside of the 847 and
377 region are also critical to MAS promoter regulation but
were missed because of the nature of promoter cleavage series,
we performed mutations at the distal (1855) triple SOX
binding site and the proximal SOX binding site (86). Both
mutations result in upregulation of the MAS promoter in CHO
cells, with significance seen with the mutation at 1855 and a
trend seen at 86 (Fig. 2E). To further validate the in vitro
confirmed SOX binding site in MAS at86, we used the short
MAS promoter construct [MAS(377/4)], again mutating
the SOX binding element, recovering the mutations, and mu-
tating it to a different sequence than the first mutation (Fig.
2F). Mutation at the SOX binding site for both changes
(MutSOX-86 and Mut2SOX-86) resulted in around fivefold
upregulation of the MAS promoter, while recovery of the
mutation (RecSOX-86) yielded similar values as the wild-type
MAS promoter. DNA probes for the MAS promoter containing
this SOX binding site can be bound by both 6X His-tagged and
GST-tagged SRY protein (Fig. 2G). The data on the MAS
promoter indicate that SRY and SOX3 regulate the MAS
promoter in cis through a combination of multiple SOX bind-
ing sites. The ENCODE data that the MAS promoter is regu-
lated through the GATA 2/3 transcription factors reaffirm our
interests of the SOX gene regulation, as many promoters have
been shown to contain competitive SOX and GATA mecha-
nisms (34, 42, 43).
Moving from MAS to the other promoters of renin angio-
tensin system, for two of the promoters that are similarly
regulated by SRY and SOX3, the next step was to determine if
both proteins operate by the same mechanism or if they result
in synergistic or additive regulation. The upregulated AGT
promoter had a concentration-dependent activation by SRY
and SOX3, with SRY&SOX3 simultaneous treatment resulting
in a similar activation as SRY or SOX3 alone (Fig. 3A). The
downregulated promoter of ACE2 was also regulated in a
concentration-dependent manner with SRY&SOX3 again re-
sulting in a similar activation as SRY or SOX3 alone (Fig. 3B).
Both results suggest that SRY and SOX3 regulation have an
overlapping mechanism in promoter control.
To address possible mechanistic insight into the different
regulation of the Ren promoter by SRY and SOX3, an analysis
of conserved transcription factor binding sites was performed
on the Ren promoter to determine if there were any Sox
consensus binding sequences (Fig. 4). The 5=-region of the Ren
gene is located 30 kB from its close syntenic gene KISS1,
with very few conserved ECRs located in the intergenic space
(Fig. 4A). Addressing the proximal promoter of Ren, we found
an 500 bp ECR (Fig. 4B) to contain 12 conserved transcrip-
tion factor binding sites (Fig. 4C), none of which are SOX
binding elements. The REN(1444/8) promoter driving our
luciferase production contains a total of three SOX binding
elements located 1 kB from the transcriptional start site
(TSS), outside the ECR (Fig. 4D). A TATA box is located 29
bps away from the TSS, suggesting proper distance for tran-
scriptional initiation (Fig. 4D).
Delivery of SRY only at 50 ng, and not 25 ng, significantly
upregulated the Ren promoter, while both concentrations of
SOX3 result in downregulation of the promoter (Fig. 5A).
Surprisingly, delivery of SRY&SOX3 results in a repression
similar to SOX3 alone (Fig. 5A), suggesting that regulation
mechanisms differ between SRY and SOX3 on the Ren pro-
moter. To further understand this difference, we tested the
REN(1444/8) promoter with members of each SOX sub-
family (Fig. 5B). The promoter was significantly regulated by
SRY (upregulated), SOX2 (downregulated), and SOX3 (down-
regulated). It should be noted that SOX2 and SOX3 are both
members of the SOXB1 subfamily, with highly conserved
sequence and function (30). Removal of all three SOX binding
elements in this promoter construct resulted in an increase in
promoter activity for all SOX constructs (except SOX30) with
Fig. 3. Similar mechanisms of regulation by SRY and SOX3 on promoters of AGT and ACE2. A: activation of the AGT promoter with 2 concentrations of
transfected SRY (light gray) or SOX3 (dark gray). In addition, a double transfection of SRY and SOX3 (checkered) shows nonadditive activation suggesting
shared mechanisms of promoter control. B: repression of the ACE2 promoter with 2 concentrations of transfected SRY (light gray) or SOX3 (dark gray). In
addition a double transfection of SRY and SOX3 (checkered) shows nonadditive repression, suggesting shared mechanisms of promoter control. Error bars are
shown as the SE. Each sample is compared with the control for each promoter. *Significant differences (P  0.05).
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complete loss of promoter repression seen in the SOX2 and
SOX3 treated cells (Fig. 5C). This suggests that Ren promoter
repression seen by SOX3 and SOX2 is a cis-acting function,
while the activation by SRY is likely a trans-acting function.
To understand the context for SRY and SOX3 regulation of
the RAS, we performed an analysis of tissue expression in the
rat, an organism with extensive work done to characterize the
protein products of the RAS (51). Using unannotated (for Sry
and Sox3) RNA-Seq datasets from the rat BodyMap project
(71), we determined Sry and Sox3 expression profiles using
320 RNA-Seq experiments for 10 tissues of male and female
Fisher 344 rats (Fig. 6). Global expression showed identifi-
able transcripts for Sry in all male tissues; however, Sox3
transcripts were detected only in male and female brain and
the male testis (Fig. 6A). The testis (Fig. 6B) and brain (Fig.
6C) both had expression of Sry and Sox3 in the four age
groups of male rats, while in the kidney only Sry transcripts
were detected (Fig. 6D). The kidney is the primary source
for Ren found in the blood and is thus the top tissue of
interest for Ren regulation control in blood pressure. The rat
Fig. 4. Promoter analysis of the gene renin (Ren). A: ECR browser analysis of the intergenic space (roughly 30 kB) between Renin (REN) and the syntenic KiSS-1
metastasis-suppressor gene (KISS1) for the rat (rn4), mouse (mm10), dog (canFam2), and monkey (rh2Mac2). Regions in blue are protein coding exons, yellow
are untranslated regions (UTRs), and those in red and green share conservation with human based on 20 bp stretches sharing  90% homology. B: ECR browser
analysis for the proximal promoter of REN with regions in red and green showing conservation of 50 bp stretches with 50% homology. C: the large ECR in the
proximal promoter of REN was analyzed for shared transcription factor (TF) binding sites between human and rat using the RVISTA software selecting for all
possible TFs. D: the sequence of REN(1444/8) pGL3 promoter construct identifying the TATA box (red, highlighted yellow) located within the proper
distance of the 5=-UTR (highlighted yellow). Additionally the conserved TF sites are colored relative to that in C. The 3 potential SOX binding sites (highlighted
in red) fall outside of the ECR.
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expression profile for Sox3 closely matches that of the
human protein atlas for human SOX3 (http://www.protein-
atlas.org/ENSG00000134595-SOX3/tissue). In some of the
human protein atlas RNA and protein expression samples,
SRY was detectable in the kidney (http://www.proteinatlas.
org/ENSG00000184895-SRY/tissue/kidney#img). We
therefore tested primate expression of SRY and SOX3 using
publically available SRA datasets for RNA-Seq of kidney
and testis. While SRY and SOX3 were both detected in the
testis of primates, only SRY could be detected in the kidney
(Fig. 6E).
DISCUSSION
There are sex differences in the prevalence of many condi-
tions including cardiovascular diseases, asthma, autoimmune
disorders, birth defects, neurological disorders, and cancers
(47). Of these diseases, the RAS has been associated with the
cardiovascular, respiratory, neurological, reproductive, and im-
mune systems along with cancer progression (24, 27, 41, 54,
68). Sry transcripts/proteins have been identified in all of these
tissue types in the rat and in the human (64, 67). Part of the sex
disparities for blood pressure is due to hormonal contributions
(57), but additional evidence points to sex chromosome con-
tributions (10, 11, 60). Previous research from our group has
established animal models for Y chromosome-specific eleva-
tion of blood pressure (21) and behavior alteration (14, 63) in
the rat, narrowing down the entire Y chromosome to the Sry
gene (19). This has opened up the question of whether SRY
function in blood pressure control might be conserved from the
divergence of the mammalian X-chromosome gene SOX3 or
whether the regulation is novel to SRY.
Genes on the Y chromosome evolve much faster than their
X-chromosome homologs or other autosomal genes due to a
loss of crossover, the founder effect, and increased mutagen-
esis in the testis (25). In our data we confirm this, with SOX3
protein sequences from a broad range of vertebrates highly
conserved for the HMG box; however, the HMG box of SRY
found in a small subset of vertebrates (mammals) has a higher
rate of divergence (Fig. 1). Still, structural and functional
assessment of these sequences confirms that DNA binding
through the HMG box is similar between SRY and SOX3,
maintaining the critical amino acids for proper DNA contact,
with sequence divergence between SRY and SOX3 found at
amino acids that do not contribute to the folding of the domain
or DNA contact.
The solid number of studies pointing to sex-specific differ-
ences in RAS modulation (26) and our previous data showing
SRY regulation of the RAS genes both in vitro (40, 53) and in
vivo (19), in combination with the conserved DNA binding
between SRY and SOX3, lead us to hypothesize that the
promoter regions of the RAS genes may be regulated by both
SRY and SOX3 transcription factors, which may potentially
contribute to sex differences in blood pressure regulation. The
promoter of AGT was upregulated by both SRY and SOX3,
while the promoters of ACE2, AT2, and MAS were downregu-
lated by both SRY and SOX3. The only promoter that was
differentially regulated was that of REN, which was upregu-
lated by SRY and downregulated by SOX3. This suggests that
SRY has gained a novel protein function from its homolog,
SOX3, in trans-regulating Ren (or loss of cis-regulation seen
by SOX3) while maintaining the regulation of genes such as
AGT, ACE2, AT2, and MAS. As many of the experiments
shown in this study are based on luciferase promoter con-
structs, the size of these constructs may influence the outcomes
of the SRY/SOX3 regulation with potential regulation left out
of the construct design. However, the constructs as designed
show promoter regulation that is supported by the in vivo Sry
electroporation studies in the rat (19) and thus likely contain
the minimal promoter for Sry regulation in vivo. It is also
possible that regions outside of the HMG box of SRY and
SOX3 control the differences seen in regulation of Ren. Ren,
primarily produced in the kidney, is the rate-limiting step of the
RAS. Thus the activation by SRY, which is expressed in the
kidney, might contribute to elevation of blood pressure through
increased ANG II peptide; however, SOX3 does not appear to
regulate this step. A decrease in the ANG-(1–7) arm of the
RAS maintained in SRY- and SOX3-treated cells further po-
tentiates blood pressure elevation control by SRY. The andro-
gen receptor is known to directly interact with SRY and
regulate gene promoters (70), suggesting potential for syner-
gistic effects between Sry and androgen signaling to contribu-
tion to sex differences in blood pressure.
The rat is a well-established model organism for understanding
the contributions of the Y chromosome on phenotype. Almost 25
years ago, crosses of the Y chromosome from the spontaneously
hypertensive rat (SHR) (21) and the SHR stroke prone (13) with
the normotensive WKY rat resulted in blood pressure elevation,
while the reciprocal crosses reduces blood pressure in the SHR
rat. Crosses of the Brown Norway (BN) Y chromosome onto the
SHR were also able to reduce blood pressure (31). Recently,
crosses for the Y chromosome from the salt-sensitive rat, with
salt-dependent blood pressure increases, to the normotensive BN
Fig. 5. Regulation of the REN promoter by various SOX proteins. A: activation
of the REN promoter with 2 concentrations of transfected SRY (light gray) or
repression by 2 concentrations of SOX3 (dark gray). In addition a double
transfection of SRY and SOX3 (checkered) showed downregulation of the
promoter similar to that of SOX3 transfected cells. B: transfection of CHO
cells with either the control pEF1 vector (black) or 1 of the SOX pEF1
constructs (gray) along with the pGL3 REN(1444/8) luciferase vector.
Error bars are shown as the SE. Each sample is compared with the control for
each promoter. *Significant differences (P  0.05). C: the REN(1444/8)
promoter construct was mutated to remove each of the 3 SOX binding sites;
this construct was named REN(1444/8) SOX mut. The mutant pGL3
construct (gray) was transfected with each of the SOX pEF1 expression vectors
resulting in an increase in promoter activity relative to the wt pGL3 promoter
construct (black) for all but the SOX30 vector (n  1).
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altered kidney function (39). These rat consomic animals establish
needed model organisms to translate the literature of human
Y-chromosome contributions to blood pressure (11, 18, 60).
Details in this article provide the first molecular mechanisms for
differences in homologous transcription factors found on the X or
Y chromosome to contribute to sex differences in blood pressure
regulation.
In the rat and human, Sry is expressed in numerous tissues
including testis, brain, heart, and kidney (64); however, Sox3
expression appears to be limited to the brain and testis. In addition
to testis development (69), Sox3 has been proposed to be critical
for brain development, particularly for the hypothalamic-pituitary-
adrenal axis (HPA) (46, 56). In the brain, proteins of the RAS
have been shown to contribute to the HPA (36), an axis with
known sex differences (33, 66). In the classical RAS, ANG II acts
on the pituitary to release vasopressin and ACTH. These pituitary
cell lineages are developmentally regulated by SOX3 (1), such
that they are likely activated by the ACE/ANG II/AT1 axis of the
Fig. 6. Expression profile for Sry and Sox3 in the rat using data from the Rat BodyMap project. Expression profile for Sox3 (gray) and Sry (black) in female (F)
and male (M) RNA-Seq data for 10 tissues in the Fisher 344 rat (A). Each tissue is a pool of 16 individual RNA-Seq experiments (4 animals at 4 ages). Data
are shown as reads per kilobase per million (RPKM). While Sry is ubiquitously expressed in male only, Sox3 transcripts are found at all 4 ages (2, 6 21, and
104 wk old rats) in the male testis (B) and brain (C). The kidney showed expression of Sry at all 4 ages with no detectable Sox3 reads (D). Error bars for the
individual tissues (B–D) represent the SE of 4 independent RNA-Seq datasets at each age. E: analysis of primate (Homo sapiens, Gorilla gorilla, Macaca mulatta,
Pan troglodytes) kidney and testis SRA datasets for expression of SOX3 (gray) or SRY (black). Expression of both SRY and SOX3 are seen in testis, while only
SRY expression is found in kidney.
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RAS. In concert, the ACE 2/ANG-(1–7)/MAS axis of the RAS is
repressed in the pituitary (16). It is of interest to note that in the rat
models of Y-chromosome crosses, behavioral differences have
also been seen in males (14). With the brain RAS shown to be
involved in neurological development (5, 44) and RAS inhibitors
given during pregnancy associated with mental delays in the
offspring (7), our data also suggest a potential impact on sex
differences in brain development through the RAS regulation.
In summary, the fact that SOX3 functions in the brain
combined with the documented literature above on RAS in
brain development leads us to suggest that regulation of mul-
tiple RAS proteins in the brain was inherited and selected on
following the X/Y split in mammals, with SRY gaining addi-
tional expression in tissues such as the kidney and trans
regulation of genes such as Renin resulting in a male-specific
modulation of blood pressure.
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